Literature DB >> 27122492

Aldosterone is associated with left ventricular hypertrophy in hemodialysis patients.

Greicy Mara Mengue Feniman De Stefano1, Silméia Garcia Zanati-Basan2, Laercio Martins De Stefano2, Viviana Rugolo Oliveira E Silva2, Patrícia Santi Xavier2, Pasqual Barretti2, Roberto Jorge da Silva Franco2, Jacqueline Costa Teixeira Caramori2, Luis Cuadrado Martin2.   

Abstract

OBJECTIVES: Patients with chronic kidney disease present a higher degree of left ventricular hypertrophy than expected for hypertension levels. In chronic kidney disease the plot between the quotient extracellular water/total body water and aldosterone is shifted up and to the right. There are few studies that verified the role of aldosterone in cardiac remodeling in this set of patients. The aim of this study was to evaluate the relationship between serum aldosterone and left ventricular mass index in patients with chronic kidney disease on hemodialysis.
METHODS: The patients were submitted to clinical and laboratory evaluation, bioelectrical impedance, echocardiography and ambulatory blood pressure monitoring. The 27 patients included were divided into two groups according to aldosterone level and compared with each other.
RESULTS: The group of patients with higher aldosterone levels had higher left ventricular mass index. These groups were heterogeneous with regard to ambulatory systolic blood pressure, body mass index, and aldosterone levels and homogeneous with regard to the quotient extracellular water/total body water, renin-angiotensin-aldosterone system blockers, beta blocker use and other clinical characteristics. The association between aldosterone levels and left ventricular mass index was adjusted to confounding variables by a multiple linear regression analysis in which aldosterone was independently associated with left ventricular mass index.
CONCLUSION: The data presented are consistent with a pathogenic role of aldosterone in left ventricular hypertrophy in patients with chronic kidney dialysis in dialysis patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01128101.
© The Author(s), 2016.

Entities:  

Keywords:  aldosterone; hemodialysis; left ventricular hypertrophy

Mesh:

Substances:

Year:  2016        PMID: 27122492      PMCID: PMC5933569          DOI: 10.1177/1753944716644583

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  36 in total

1.  Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.

Authors:  A Levin; C R Thompson; J Ethier; E J Carlisle; S Tobe; D Mendelssohn; E Burgess; K Jindal; B Barrett; J Singer; O Djurdjev
Journal:  Am J Kidney Dis       Date:  1999-07       Impact factor: 8.860

2.  Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis.

Authors:  Carmine Zoccali; Francesco Antonio Benedetto; Francesca Mallamaci; Giovanni Tripepi; Giuseppe Giacone; Alessandro Cataliotti; Giuseppe Seminara; Benedetta Stancanelli; Lorenzo Salvatore Malatino
Journal:  J Am Soc Nephrol       Date:  2001-12       Impact factor: 10.121

3.  Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.

Authors:  Guilhem du Cailar; Pierre Fesler; Jean Ribstein; Albert Mimran
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

4.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

5.  Aldosterone 'escape' vs 'breakthrough'.

Authors:  Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2010-02       Impact factor: 28.314

6.  Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.

Authors:  Maren Leifheit-Nestler; Robert Große Siemer; Kathrin Flasbart; Beatrice Richter; Felix Kirchhoff; Wolfgang H Ziegler; Michael Klintschar; Jan U Becker; Andreas Erbersdobler; Christoph Aufricht; Tomas Seeman; Dagmar-Christiane Fischer; Christian Faul; Dieter Haffner
Journal:  Nephrol Dial Transplant       Date:  2015-12-17       Impact factor: 5.992

Review 7.  The incidence and implications of aldosterone breakthrough.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Nat Clin Pract Nephrol       Date:  2007-09

8.  Adiponectin and Aldosterone in Left Ventricular Hypertrophy: An Intriguing Interplay.

Authors:  Panagiotis Anagnostis; Niki Katsiki; Vasilios G Athyros; Asterios Karagiannis
Journal:  Angiology       Date:  2014-03-31       Impact factor: 3.619

Review 9.  Myocardial remodeling in low-renin hypertension: molecular pathways to cellular injury in relative aldosteronism.

Authors:  Syamal K Bhattacharya; Malay S Gandhi; German Kamalov; Robert A Ahokas; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

10.  Is inappropriate left ventricular mass related to neurohormonal factors and/or arterial changes in hypertension? A LIFE substudy.

Authors:  M H Olsen; K Wachtell; G de Simone; V Palmieri; H Dige-Petersen; R B Devereux; H Ibsen; J Rokkedal
Journal:  J Hum Hypertens       Date:  2004-06       Impact factor: 3.012

View more
  4 in total

1.  The relationship between Aldosterone level and various LV conditions in patients with End-stage renal disease.

Authors:  Vida Nesarhosseini; Hossein Mohsenipouya; Atieh Makhlough; Rozita Jalalian
Journal:  Caspian J Intern Med       Date:  2019

2.  Intradialytic hypotension and cardiac remodeling: should we consider the renin-angiotensin-aldosterone system?

Authors:  Juanli Wang; Wenjun Zhang; Yuanyuan Qi
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

3.  The Gene Polymorphism of Angiotensin-Converting Enzyme Intron Deletion and Angiotensin-Converting Enzyme G2350A in Patients With Left Ventricular Hypertrophy: A Meta-analysis.

Authors:  Jonny Karunia Fajar; Budi Susetio Pikir; Erdo Puncak Sidarta; Putu Nina Berlinda Saka; Rizal Rahmanda Akbar; Teuku Heriansyah
Journal:  Indian Heart J       Date:  2019-07-06

4.  Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy.

Authors:  Kohei Okamoto; Hideki Fujii; Kentaro Watanabe; Shunsuke Goto; Keiji Kono; Shinichi Nishi
Journal:  J Endocr Soc       Date:  2021-12-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.